

November 28, 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 04 2001

Applicant:

Shmuel A. Ben-Sasson

Application No.: 09/736,076

Group: 1646

Filed:

December 13, 2000

Examiner: Unknown

For:

Short Peptides Which Selectively Modulate the Activity of Serine/Threonine Kinases

TECH CENTER 1600/2900

Date: 11/29/01

EXPRESS MAIL LABEL NO. EVO10678499 US

TRANSMITTAL OF REVOCATION OF POWER OF ATTORNEY
AND APPOINTMENT OF NEW ATTORNEYS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed herewith are two (2) executed Revocations of Power of Attorney and Appointment of New Attorneys along with two (2) executed Certificates under 37 C.F.R. § 3.73(b) for filing in the captioned application.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Richard W. Wagner

Richard W. Wagner
Registration No.: 34,480
Tel.: (978) 341-0036
Fax: (978) 341-0136

Concord, MA 01742-9133

Date: November 29, 2001



RECEIVED

DEC 04 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: 1242.1015-009

In re Application of:)
Shmuel A. Ben-Sasson)
Appln. No.: 09/736,076) Washington, D.C.
Filed: December 13, 2000)
For: Short Peptides Which)
Selectively Modulate the)
Activity of Serine/Threonine)
Kinases)

**REVOCATION AND NEW POWER OF ATTORNEY
(FOR APPLICATION)**

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

The Children's Medical Center Corporation, a corporation having a principal place of business at 300 Longwood Avenue, Boston, Massachusetts 02115 (hereinafter "ASSIGNEE"), hereby certifies that they are the assignee of an undivided 50% of the entire right, title and interest of the above-identified patent application by virtue of an assignment from the inventors of the above-identified patent application recorded May 17, 2001, at Reel 011805, Frame 0410-0412. The undersigned (whose title is supplied below) is empowered to sign this document on behalf of the assignee.

The Children's Medical Center Corporation hereby revokes any and all previous Powers of Attorney and appoints all of the

practitioners associated with Customer Number 001444, currently SHERIDAN NEIMARK Reg. No. 20,520, ROGER L. BROWDY, Reg. No. 25,618, ANNE M. KORNBAU, Reg. No. 25,884, NORMAN J. LATKER, Reg. No. 19,963, IVER P. COOPER, Reg. No. 28,005, JAY M. FINKELSTEIN, Reg. No. 21,082, and ALLEN C. YUN, Reg. No. 37,971 (Patent Agent), all of 624 Ninth Street, N.W., Suite 300, Washington, D.C. 20001, as its attorneys, each with full power of substitution, association and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith. Please direct all further correspondence with respect to this application to the address associated with Customer Number 001444, namely:

BROWDY AND NEIMARK
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

Respectfully submitted,


THE CHILDREN'S MEDICAL CENTER
CORPORATION

By: Donald P. Lombardi

Date: 26 November 2001

Donald P. Lombardi
(Typed Name)

Chief Intellectual Property Officer
(Office)

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)**RECEIVED**

DEC 04 2001

Applicant: Shmuel Ben-SassonApplication No.: 09/736,076Filed: December 13, 2000For: Short Peptides Which Selectively Modulate the Activity of Serine/Threonine Kinases

TECH CENTER 1600/2900

The Children's Medical Center Corporation

(Name of Assignee)

, a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

certifies that it is

- A. ☐ the assignee of the entire right, title and interest in the patent application identified above.
- B. ☒ an assignee of an undivided 50% of the entire right, title and interest in the patent application identified above. Yissum Research Development Company is the assignee of the other undivided 50% of the entire right, title and interest in the patent application identified above.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 011805, Frame 0410-0412 or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are attached.☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 26 November 2001Name: Donald P. LombardiTitle: Chief Intellectual Property OfficerSignature: Donald P. Lombardi

::ODMA\HODMA\manage;270996;1



RECEIVED

DEC 04 2001

TECH CENTER 1600/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: 1242.1015-009

In re Application of:)
Shmuel A. Ben-Sasson)
Appln. No.: 09/736,076) Washington, D.C.
Filed: December 13, 2000)
For: Short Peptides Which)
Selectively Modulate the)
Activity of Serine/Threonine)
Kinases)

REVOCATION AND NEW POWER OF ATTORNEY
(FOR APPLICATION)

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Yissum Research Development Company, a corporation having a principal place of business at 46 Jabotinsky Street, Jerusalem 91042, Israel (hereinafter "ASSIGNEE"), hereby certifies that they are the assignee of an undivided 50% of the entire right, title and interest of the above-identified patent application by virtue of an assignment from the inventors of the above-identified patent application recorded May 17, 2001, at Reel 011805, Frame 0419-0421. The undersigned (whose title is supplied below) is empowered to sign this document on behalf of the assignee.

Yissum Research Development Company hereby revokes any and all previous Powers of Attorney and appoints all of the

In re of Appln. No. 09/736,076

practitioners associated with Customer Number 001444, currently
SHERIDAN NEIMARK Reg. No. 20,520, ROGER L. BROWDY, Reg. No.
25,618, ANNE M. KORNEAU, Reg. No. 25,884, NORMAN J. LATKER, Reg.
No. 19,963, IVER P. COOPER, Reg. No. 28,005, JAY M. FINKELSTEIN,
Reg. No. 21,082, and ALLEN C. YUN, Reg. No. 37,971 (Patent
Agent), all of 624 Ninth Street, N.W., Suite 300, Washington,
D.C. 20001, as its attorneys, each with full power of
substitution, association and revocation, to prosecute this
application and to transact all business in the Patent and
Trademark Office in connection therewith. Please direct all
further correspondence with respect to this application to the
address associated with Customer Number 001444, namely:

BROWDY AND NEIMARK
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

Respectfully submitted,

YISSUM RESEARCH DEVELOPMENT
COMPANY

By: Avi Barak Renée Ben-Israh

Date: 21 November 2001

ABRAHAM BARAK RENÉE BEN ISRAEL

PRESIDENT and
Chief Executive Officer
(Office)

V.P. INTELLECTUAL
PROPERTY

